EUVIMEDEUVIMED entdecken
Crossref

Acute neonatal effects following prenatal venlafaxine exposure

Chrishanthi Harideep, Per Damkier, Karina Dyrvig Honoré

Ugeskrift for Læger · 19.10.2026 · 1-4

DOI: 10.61409/v03260181 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Ugeskrift for Læger, online erschienen am 19.10.2026. Verfasst von Chrishanthi Harideep und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Venlafaxine is a serotonin-noradrenaline reuptake inhibitor. Intrauterine exposure may cause neonatal withdrawal symptoms known as poor neonatal adaptation syndrome (PNAS). In this case report, we present a term newborn with respiratory distress and neurological hyperexcitability after birth following maternal venlafaxine treatment. Evaluation excluded infectious and neurological causes, and symptoms resolved in days. PNAS should be considered despite early symptoms. Regional variation in observation practices may affect recognition of PNAS, underscoring the need for awareness of the condition.

Zitieren

APA

Harideep, C., Damkier, P., & Honoré, K. D. (2026). Acute neonatal effects following prenatal venlafaxine exposure. Ugeskrift for Læger, 1-4. https://doi.org/10.61409/v03260181

Vancouver

Harideep C, Damkier P, Honoré KD. Acute neonatal effects following prenatal venlafaxine exposure. Ugeskrift for Læger. 2026:1-4. doi:10.61409/v03260181

BibTeX
@article{Harideep2026,
  author = {Harideep, Chrishanthi and Damkier, Per and Honoré, Karina Dyrvig},
  title = {Acute neonatal effects following prenatal venlafaxine exposure},
  journal = {Ugeskrift for Læger},
  year = {2026},
  pages = {1--4},
  doi = {10.61409/v03260181}
}
Kostenlos starten →